Abstract: Light emitting devices and methods for their manufacture are provided. According to one aspect, a light emitting device is provided that comprises a substrate having a recess, and an interlayer dielectric layer located on the substrate. The interlayer dielectric layer may have a first hole and a second hole, the first hole opening over the recess of the substrate. The light emitting device may further include first and second micro LEDs, the first micro LED having a thickness greater than the second micro LED. The first micro LED and the second micro LED may be placed in the first hole and the second hole, respectively.

Abstract: Aspects of the present invention are related to systems and methods for estimation of additive noise in an image or in a video sequence. An additive-noise estimate may be computed based on a first significant peak in a histogram of standard-deviation values of patches of an image-channel image associated with an input image.

Abstract: The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Abstract: This backlight device 2 is provided with: a light source; a plurality of stacked optical sheets 22, 23, and 24 through which the light from the light source passes; and a frame member 28 to which the plurality of optical sheets 22, 23, and 24 are affixed. The respective plurality of optical sheets 22 to 24 is provided with protrusions 221, 231, and 241 that protrude in a direction parallel to the sheet surface at a portion of the edge thereof. The protrusions 221, 231, and 241 respectively have: first regions 221a, 231a, and 241a that are provided to the root side and that do not overlap the protrusions of the other optical sheets; and second regions 221b, 231b, and 241b that are provided to the tip side and of which at least a portion overlaps the protrusions of the other optical sheets.

Abstract: Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (CETP) and are expected to have utility in raising HDL-C, lowering LDL-C, and in the treatment and prevention of atherosclerosis.

Abstract: The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.

Abstract: The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: If dual connectivity is configured, and a first cell group includes a primary cell and an uplink physical channel in a second cell group is a physical uplink control channel in the second cell group, power of the uplink physical channel in the second cell group is determined on the basis of whether PSCG, which is the maximum transmit power of the second cell group, is exceeded, and PSCG is calculated through computation using at least PCMAX, PMeNB, and power of the physical uplink control channel in the first cell group.

Abstract: An illuminating device capable of stably illuminating an irradiated object such as a document while suppressing light loss with a simply structure is provided. An LED array and a reflective plate are disposed sandwiching a slit (St) through which light reflected by a document MS passes and a light-guiding member is disposed on the side of the LED array. The light-guiding member includes a direct emission unit disposed between an illumination range y centered on a document reading position and the LED array and an indirect emission unit disposed between the reflective plate and the LED array, a light incidence face of the direct emission unit and a light incidence face of the indirect emission unit are disposed at mutually different position around the LED array, and the LED array is disposed on a side of an interior angle formed by the light incidence faces.

Abstract: A method for crystallizing insulin or insulin analogs under alkaline conditions in the presence of zinc, purifying the crystals by filtering through a filter, and drying the crystals captured on the filter to produce crystalline insulin or insulin analog compositions is described. Method has been exemplified with insulin lispro.

Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Abstract: A first resource for transmission of first information is configured, a second resource for transmission of second information is configured, a third resource for transmission of a first synchronization signal and transmission of third information for indicating a frame number is configured, a fourth resource for transmission of a second synchronization signal and transmission of fourth information for indicating a frame number is configured, and a transmit power for each of the transmission of the first synchronization signal, the transmission of the third information, the transmission of the second synchronization signal, and the transmission of the fourth information is given by using one third parameter that is configured in a higher layer and that is common to the transmission of the first synchronization signal, the transmission of the third information, the transmission of the second synchronization signal, and the transmission of the fourth information.

Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Abstract: The present disclosure provides a resource release and reuse mechanism while switching between Mode 1 and Mode 2 in a D2D communication system. According to an embodiment of the present disclosure, a method comprises: detecting a network condition during a D2D Mode 1 transmission and reporting the detected network condition to a base station to assist the base station in timely releasing physical resources scheduled for the terminal when the transmission is interrupted; and holding data scheduled to transmit in the interrupted transmission in response to the detected network condition satisfying a triggering condition of data reception interruption, and switching from Mode 1 to Mode 2 for transmitting the held data in Mode 2; or waiting for re-accessing an original cell and returning to Mode 1 for transmitting the held data in Mode 1.

Abstract: In order to (i) secure a display region of a screenshot and (i) display at least one of a title of a web page and a URL of the web page on which the screenshot is based, the smartphone (200, 300) includes a fifth display control section (71) configured to display the at least one of the title and the URL so that the at least one of the title and the URL overlaps with the screenshot.

Abstract: The present invention provides a method for producing a liquid crystal display device which can produce a liquid crystal display device with favorable voltage holding ratio reliability and reduced image sticking.

Abstract: A microwave oven has a magnetron (11) which generates microwaves to heat a heating object, and a control unit (100) which controls the magnetron (11). During heating operation in which the heating object is heated with microwaves generated from the magnetron (11), the control unit (100) controls the magnetron (11) so as to suppress abnormal operations of the magnetron (11) in response to a status of power supply supplied from outside.

Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein D1, D2 and D3 are each N, CH, or substituted CH, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

Abstract: A first parameter that is used for configuration of a cyclic prefix for transmission of first information is configured, a second parameter that is used for configuration of a cyclic prefix for transmission of second information is configured, and one third parameter that is used for configuration of cyclic prefixes for transmission of a first synchronization signal, transmission of third information, transmission of a second synchronization signal, and transmission the fourth information, and that is common to the transmission of the first synchronization signal, the transmission of the third information, the transmission of the second synchronization signal, and the transmission of the fourth information is configured.